Completed Research: CLINICAL/TRANSLATIONAL RESEARCH
Abstract #CR03

Treatment Patterns, Real-World Outcomes, and Resource Use in Patients with Non–MSI-High or Mismatch Repair Proficient Advanced Endometrial Cancer

JHOP - March 2022 Vol 12 Special Feature - HOPA Abstracts, Gynecologic Cancers

Presenter: Vimalanand S. Prabhu, BE, MMgmt, PhD, Director, Outcomes Research, Merck & Co, Inc

Co-Authors: Sneha Kelkar, MSc, MPH, Open Health, Bethesda, MD; Shelby Corman, PharmD, MS, BCPS, Open Health, Bethesda, MD; Cynthia Macahilig, MR, RTI-Health Solutions, Research Triangle Park, NC; Jingchuan Zhang, PhD, Eisai Inc; Nifasha Rusibamayila, MPH, Open Health, Bethesda, MD; Shardul Odak, PharmD, MD, RTI-Health Solutions, Research Triangle Park, NC; Linda Duska, MD, MPH, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Virginia School of Medicine, Charlottesville, VA

BACKGROUND: Chemotherapy, the standard of care for patients with advanced endometrial cancer,1 has suboptimal outcomes. In 2019, novel therapies specific to microsatellite instability (MSI) or mismatch repair (MMR) status changed the treatment landscape in the United States,2 but real-world outcomes data by MSI or MMR status are sparse.

OBJECTIVE: To assess treatment patterns, real-world outcomes, and hospitalization stratified by treatment category, in patients with advanced endometrial cancer and non–MSI-high (MSI-H) or MMR proficient tumors in the United States.

METHOD: Endometrial Cancer Health Outcomes (ECHO) is a multicenter, retrospective, chart review US study in which physicians consented to participate and provided de-identified data for adult women with inoperable non–MSI-H or MMR proficient advanced endometrial cancer. Patients had received ≥1 previous systemic therapies and had disease progression between July 1, 2016, and June 30, 2019. Data collected included patient demographics, clinical characteristics, treatment category, clinical outcomes, and hospitalization. Kaplan-Meier analyses were performed to estimate time to treatment discontinuation, real-world progression-free survival (PFS) and overall survival (OS), stratified by chemotherapy or hormonal therapy. The study protocol was approved by the Institutional Review Board.

RESULTS: The study included 139 patients (average age, 64 years). Approximately 64% of the patients were white, and 53% had ECOG performance score of ≥2. For second-line therapy, 114 patients received chemotherapy, and 25 patients received hormonal therapy, with a median follow-up of 9 and 8 months, respectively. The median time to treatment discontinuation was 6 months in the hormonal therapy group and 4 months in the chemotherapy group. The median OS since the initiation of second-line therapy in the hormonal therapy and chemotherapy groups was 9 and 10 months, respectively; the median real-world PFS was 6 and 5 months, respectively; and the best overall response to second-line therapy was 24% and 42%, respectively. A total of 16% of the patients had ≥1 hospitalizations (mean length of stay, 6 days for the hormonal therapy group and 7 days for the chemotherapy group); of the hospitalized patients, 41% had an intensive care unit stay (mean, 2 days and 5 days for the hormonal therapy and chemotherapy groups, respectively).

CONCLUSION: These results show that there continues to be significant clinical unmet need in patients with non–MSI-H or MMR proficient advanced endometrial cancer in the United States, indicating the need for novel therapies that delay disease progression, improve OS, and/or reduce hospitalization rates for this patient population.

  1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Uterine Neoplasms. Version 3.2021. June 3, 2021. Accessed July 7, 2021.
  2. Makker V, Green AK, Wenham RM, et al. New therapies for advanced, recurrent, and metastatic endometrial cancers. Gynecol Oncol Res Pract. 2017;4:19. doi: 10.1186/s40661-017-0056-7.
Related Items
Clinical Pharmacist–Initiated Tyrosine Kinase Inhibitor Discontinuation in Patients with Chronic Myeloid Leukemia
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
Evaluation of Chemotherapy-Induced Myelosuppression in Patients with Extensive-Stage Small-Cell Lung Cancer Who Received Trilaciclib: Retrospective Analysis of Florida Community Oncology Practices
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
Evaluation of the Safety of the New Alcohol-Containing Formulation of Cyclophosphamide
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
Health System Specialty Pharmacy Integration Impact on Prescription Fill Time
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
Invasive Fungal Disease in Patients with Hematologic Malignancies Receiving Micafungin Prophylaxis
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
Knowledge Gaps and Educational Needs for Common Cancer Therapy–Related Cardiovascular Adverse Events and Related Drug Interactions
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
Multidisciplinary Approach in Maximizing Oncology Clinic Throughput in a Comprehensive Cancer Center
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
Optimization of Rasburicase Dose for the Management of Tumor Lysis Syndrome in Community Oncology Practices
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
Pharmacist-Led 14-Day Oncolytic Drug Check-In Protocol
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
Safety of Rapid Dose Escalation of Venetoclax in Patients with Hematologic Malignancies
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: